Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its nice valuation and promising pipeline.

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a rolling basis. On any given week, the chance that a long position in GILD stock will rise is 53.04%, a modest upside bias. This is effectively our null hypothesis, the assumption of no mispricing.